Antares said the payment was related to the development of an undisclosed consumer health care product. In December 2011 Antares licensed drug delivery technology to Pfizer. Pfizer agreed to give Antares an upfront payment and milestone payments related to development and sales of the product, as well as royalties on any sales made in the first three years after product approval.
Shares of Antares Pharma rose 12 cents, or 2.8 percent, to $4.40 on Tuesday.
The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Antares Pharma Inc Plummeted Today
An FDA rejection is coming for the drugmaker's testosterone replacement therapy Xyosted.
Why Shares in Antares Pharma, Inc. Burst Today
Antares Pharma, Inc. shares tumbled after it priced its secondary stock offering.
3 Stocks Crushed by the Market This Week
Find out which health-care stocks got beaten down the most by the market over the past few days.